Cemdisiran Phase 3 trial shows significant functional and muscle strength improvements

A Phase 3 trial for Cemdisiran, developed by Regeneron and Alnylam, showed significant improvements in daily functioning and muscle strength. Treated patients saw a 4.5-point improvement in daily functioning after 24 weeks versus 2.2 points for placebo, with 76.6% achieving a clinically meaningful improvement of at least three points.

Detected & updated continuously · Source: Nebula